Form 4 for ABOS Acumen Pharmaceuticals, Inc.
Accepted 2026-01-12 00:00:00 ET · period of report 2026-01-08 · accession 0001628280-26-001896 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-01-12 | 2026-01-08+ | ABOS | Meisner Derek M | CLO, Corp Sec | S - Sale | $1.80 | -50.7K | 127.6K | -28% | -$90.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-08 | S | D | 30,092 | $1.82 | 97,548 | D | — | — | (F3) Represents the number of shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025. (F2) The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2026-01-12 | S | D | 8,548 | $1.71 | 83,800 | D | — | — | (F3) Represents the number of shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025. (F5) The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.6700 to $1.8400. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-01-09 | S | D | 5,200 | $1.76 | 92,348 | D | — | — | (F3) Represents the number of shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025. (F4) The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7100 to $1.8150. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-01-08 | S | D | 6,819 | $1.82 | 127,640 | D | — | — | (F1) Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025. (F2) The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |